×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Volver a Agenda
Session 4, Track A: Current and Emerging Regulatory Uses of Real-World Evidence
Session Chair(s)
Zohra Douida, MPharm, MS, MSc
Head, Regulatory Affairs Canada
Indivior Canada Inc., Canada
Brenda Gryfe, MSc
Director, Regulatory Affairs
TPIreg, Innomar Strategies, Canada
Stakeholders ranging from academics, industry, regulators, and health care providers have long recognized the opportunity of using real-world data (RWD) to evaluate the benefits and risks of medical products. Leveraging fit-for-purpose real world evidence (RWE) to support regulatory decision-making continues to gain ground. This session will focus on the perceived gaps in the evidence generation process and potential opportunities for future development and harmonization of RWE.
Learning Objective : At the conclusion of this session, participants should be able to:- Understand the regulatory limitations of RWE
- Predict future directions to improve RWE use in regulatory decision-making
- Highlight examples of successful regulatory decisions that were supported by RWE
Speaker(s)
Speaker
Representative Invited
FDA, United States
¿Tiene una cuenta?